$HALO
HALOZYME THERAPEUTICS, INC.

2022 Q2 Form 10-Q Financial Statement

#000115903622000038 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $152.4M $117.3M $102.0M
YoY Change 11.66% 31.74% -16.19%
Cost Of Revenue $33.94M $15.92M $21.59M
YoY Change 47.46% -12.61% -17.92%
Gross Profit $118.4M $101.4M $80.42M
YoY Change 4.39% 43.15% 1200.6%
Gross Profit Margin 77.72% 86.42% 78.84%
Selling, General & Admin $57.48M $13.83M $13.77M
YoY Change 366.49% 25.09% 32.44%
% of Gross Profit 48.53% 13.65% 17.13%
Research & Development $15.48M $11.85M $10.11M
YoY Change 91.88% 31.57% 36.59%
% of Gross Profit 13.07% 11.69% 12.57%
Depreciation & Amortization $12.55M $800.0K $773.0K
YoY Change 1468.25% 14.29% -3.38%
% of Gross Profit 10.59% 0.79% 0.96%
Operating Expenses $84.36M $25.69M $23.88M
YoY Change 313.74% 28.0% -45.82%
Operating Profit $34.06M $75.67M $56.53M
YoY Change -63.39% 49.15% -249.18%
Interest Expense -$4.049M $1.759M -$1.724M
YoY Change -331.11% -10.48% -60.82%
% of Operating Profit -11.89% 2.32% -3.05%
Other Income/Expense, Net -$945.0K $498.0K
YoY Change -527.6% 80.43%
Pretax Income $30.01M $74.41M $54.81M
YoY Change -67.21% 164.93% -25.12%
Income Tax $7.326M $14.30M -$11.96M
% Of Pretax Income 24.41% 19.22% -21.82%
Net Earnings $22.69M $60.11M $66.77M
YoY Change -75.2% 115.48% -8.74%
Net Earnings / Revenue 14.89% 51.25% 65.46%
Basic Earnings Per Share $0.16 $0.44
Diluted Earnings Per Share $159.5K $0.43 $462.9K
COMMON SHARES
Basic Shares Outstanding 137.9M shares 137.7M shares 140.8M shares
Diluted Shares Outstanding 142.2M shares 141.3M shares

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $209.4M $786.1M $740.9M
YoY Change -72.28% 2.86% 101.33%
Cash & Equivalents $90.93M $117.8M $118.7M
Short-Term Investments $118.4M $668.3M $622.2M
Other Short-Term Assets $45.60M $41.03M $40.48M
YoY Change 39.47% 33.64% 43.05%
Inventory $97.62M $47.76M $53.91M
Prepaid Expenses $57.91M $47.99M
Receivables $179.4M $113.8M $90.98M
Other Receivables $9.985M $0.00 $0.00
Total Short-Term Assets $541.9M $988.7M $926.3M
YoY Change -45.79% 4.99% 66.97%
LONG-TERM ASSETS
Property, Plant & Equipment $37.09M $6.943M $6.791M
YoY Change 266.08% -33.02% -6.88%
Goodwill $199.5M $0.00
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.78M $165.0M $169.3M
YoY Change 67.59% 1038.25% 1059.92%
Total Long-Term Assets $1.239B $173.6M $178.1M
YoY Change 4646.49% 598.06% 608.04%
TOTAL ASSETS
Total Short-Term Assets $541.9M $988.7M $926.3M
Total Long-Term Assets $1.239B $173.6M $178.1M
Total Assets $1.781B $1.162B $1.104B
YoY Change 73.65% 20.24% 90.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.23M $1.266M $1.541M
YoY Change 168.07% 136.64% -20.07%
Accrued Expenses $84.10M $19.13M $24.44M
YoY Change 336.34% 18.85% 19.32%
Deferred Revenue $1.746M
YoY Change 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $99.05M $89.55M $89.42M
YoY Change 11.08% 0.57% -77.49%
Total Short-Term Liabilities $199.5M $111.7M $117.1M
YoY Change 74.63% 3.98% -72.2%
LONG-TERM LIABILITIES
Long-Term Debt $1.147B $788.1M $787.3M
YoY Change 46.02% 0.43%
Other Long-Term Liabilities $138.3M $171.0K $544.0K
YoY Change 6000.13% -93.91% -84.3%
Total Long-Term Liabilities $1.285B $171.0K $787.8M
YoY Change 56601.32% -93.91% 22629.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $199.5M $111.7M $117.1M
Total Long-Term Liabilities $1.285B $171.0K $787.8M
Total Liabilities $1.488B $111.9M $904.9M
YoY Change 1177.24% 1.48% 113.0%
SHAREHOLDERS EQUITY
Retained Earnings $1.196M -$58.91M
YoY Change -100.28% -87.59%
Common Stock $261.9M $256.5M
YoY Change -47.77% -59.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $293.2M $260.3M $197.0M
YoY Change
Total Liabilities & Shareholders Equity $1.781B $1.162B $1.104B
YoY Change 73.65% 20.24% 90.44%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income $22.69M $60.11M $66.77M
YoY Change -75.2% 115.48% -8.74%
Depreciation, Depletion And Amortization $12.55M $800.0K $773.0K
YoY Change 1468.25% 14.29% -3.38%
Cash From Operating Activities $40.23M $47.80M $82.52M
YoY Change 9.06% -18.01% 61.8%
INVESTING ACTIVITIES
Capital Expenditures -$968.0K $490.0K -$158.0K
YoY Change 92.45% 81.48% -90.71%
Acquisitions
YoY Change
Other Investing Activities -$434.0M -$48.82M -$299.3M
YoY Change 884.9% 8.48% -597.19%
Cash From Investing Activities -$434.9M -$49.31M -$299.5M
YoY Change 875.96% 8.96% -611.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $150.0M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 367.8M $624.0K -156.0M
YoY Change -921.83% -99.82% 469.38%
NET CHANGE
Cash From Operating Activities 40.23M $47.80M 82.52M
Cash From Investing Activities -434.9M -$49.31M -299.5M
Cash From Financing Activities 367.8M $624.0K -156.0M
Net Change In Cash -26.90M -$884.0K -373.0M
YoY Change -48.69% -100.25% -554.28%
FREE CASH FLOW
Cash From Operating Activities $40.23M $47.80M $82.52M
Capital Expenditures -$968.0K $490.0K -$158.0K
Free Cash Flow $41.19M $47.31M $82.67M
YoY Change 10.18% -18.47% 56.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001159036
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2022Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2021Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P3Y
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-32335
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
HALOZYME THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0488686
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
11388 Sorrento Valley Road
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
794-8889
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
HALO
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
137949680 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117835000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118719000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
668305000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
622203000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
113762000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
90975000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
47761000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
53908000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41026000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40482000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
988689000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
926287000 USD
CY2022Q1 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8513000 USD
CY2021Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8794000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
22038000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
13414000 USD
CY2022Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
142508000 USD
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
155434000 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2022Q1 us-gaap Assets
Assets
1162248000 USD
CY2021Q4 us-gaap Assets
Assets
1104429000 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1266000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1541000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19133000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24441000 USD
CY2022Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1746000 USD
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1746000 USD
CY2022Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
89546000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
89419000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
111691000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
117147000 USD
CY2022Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2031000 USD
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2530000 USD
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
788099000 USD
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
787255000 USD
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
171000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
544000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
137888000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
137888000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
137888000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
137888000 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
138000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
138000 USD
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
261713000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
256347000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2791000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-620000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1196000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58912000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
260256000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196953000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1162248000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1104429000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117279000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89022000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15922000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18219000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11853000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9009000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13834000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11059000 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
41609000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
38287000 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
75670000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
50735000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
498000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
276000 USD
CY2022Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
CY2021Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
20960000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
1759000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
1965000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
74409000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
28086000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14301000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
191000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
60108000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
27895000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137658000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137952000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
141277000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148540000 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
60108000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
27895000 USD
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2171000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-83000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-35000 USD
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
17000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
57937000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
27864000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
60108000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
27895000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4742000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4923000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
778000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
738000 USD
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
971000 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
741000 USD
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-541000 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-351000 USD
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-80000 USD
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
CY2022Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
499000 USD
CY2021Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0 USD
CY2022Q1 halo Deferred Rent Payments
DeferredRentPayments
183000 USD
CY2021Q1 halo Deferred Rent Payments
DeferredRentPayments
203000 USD
CY2022Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
CY2021Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
20960000 USD
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-12926000 USD
CY2021Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
22787000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9339000 USD
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6298000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2513000 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9168000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2335000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6010000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6626000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
47797000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
58296000 USD
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
184815000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
120980000 USD
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
136000000 USD
CY2021Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
76000000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
490000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
270000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-49305000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-45250000 USD
CY2022Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0 USD
CY2021Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
784875000 USD
CY2022Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
0 USD
CY2021Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
369064000 USD
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
329000 USD
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
76179000 USD
CY2022Q1 halo Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised
ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
624000 USD
CY2021Q1 halo Proceeds From Payments For Issuance Of Shares Share Based Payment Arrangement Including Option Exercised
ProceedsFromPaymentsForIssuanceOfSharesShareBasedPaymentArrangementIncludingOptionExercised
-602000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
624000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
338701000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-884000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
351747000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119219000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148203000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118335000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
499950000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
309000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
288000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
179000 USD
CY2022Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
CY2021Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
95000 USD
CY2022Q1 us-gaap Stock Issued1
StockIssued1
0 USD
CY2021Q1 us-gaap Stock Issued1
StockIssued1
7865000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
196953000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4742000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
624000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-2171000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
60108000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
260256000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
151047000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4923000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13104000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-602000 USD
CY2021Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
76179000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-31000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
27895000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
67595000 USD
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
Organization and Business <div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes. Our proprietary enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. We license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology with the collaborators’ proprietary compounds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approved product and our collaborators’ approved products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, Hylenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recombinant, (“Hylenex”), and it works by breaking down hyaluronan (or “HA”), a naturally occurring carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. This temporarily increases dispersion and absorption allowing for improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> drug delivery technology (“ENHANZE”). We license the ENHANZE technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration. In the development of proprietary intravenous (IV) drugs combined with our ENHANZE technology, data have been generated supporting the potential for ENHANZE to reduce treatment burden, as a result of shorter duration of subcutaneous (SC) administration. ENHANZE may enable fixed-dose SC dosing compared to weight-based dosing required for IV administration, and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible treatment options such as home administration by a healthcare professional or potentially the patient. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of the product beyond the one of the proprietary IV drug.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (members of the Takeda group of companies) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company (“BMS”), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca PLC (“Alexion”), argenx BVBA (“argenx”), Horizon Therapeutics plc. (“Horizon”), ViiV Healthcare (the global specialist HIV Company majority owned by GlaxoSmithKline) (“ViiV”) and Chugai Pharmaceutical Co., Ltd (Chugai). We receive royalties from three of these collaborations, including royalties from sales of one product from the Baxalta collaboration, three products from the Roche collaboration and one product from the Janssen collaboration. Future potential revenues from royalties and fees from ENHANZE collaborations and the sales and/or royalties of our approved products will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to the condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Switzerland GmbH and Halozyme Switzerland Holdings GmbH.</span></div>
CY2022Q1 halo Royalties Received Number Of Collaborators
RoyaltiesReceivedNumberOfCollaborators
3 collaborator
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
Use of EstimatesThe preparation of interim unaudited condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our interim unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
500000 USD
CY2022Q1 halo Revenue Remaining Performance Obligation Period Of Termination By Written Notice
RevenueRemainingPerformanceObligationPeriodOfTerminationByWrittenNotice
P90D
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14300000 USD
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.192
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
671069000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2776000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
668305000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
622823000 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
620000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
622203000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
41 security
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
442000000 USD
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2800000 USD
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
594944000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
500965000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
73361000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
121238000 USD
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
668305000 USD
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
622203000 USD
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
786123000 USD
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
740910000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117279000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89022000 USD
CY2022Q1 halo Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets
AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
113762000 USD
CY2021Q4 halo Accounts Receivableafter Allowancefor Credit Loss Currentexcluding Other Contract Assets
AccountsReceivableafterAllowanceforCreditLossCurrentexcludingOtherContractAssets
90975000 USD
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
3777000 USD
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
4276000 USD
CY2022Q1 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
3800000 USD
CY2022Q1 us-gaap Deferred Credits And Other Liabilities
DeferredCreditsAndOtherLiabilities
3800000 USD
CY2022Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1700000 USD
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 USD
CY2022Q1 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
15840000 USD
CY2021Q4 halo Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromproductsalestocollaborators
18504000 USD
CY2022Q1 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
25619000 USD
CY2021Q4 halo Accountsreceivablefromcollaborators
Accountsreceivablefromcollaborators
5422000 USD
CY2022Q1 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
68169000 USD
CY2021Q4 halo Accountsreceivablefromroyalties
Accountsreceivablefromroyalties
63555000 USD
CY2022Q1 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
5372000 USD
CY2021Q4 halo Accountsreceivablefromproductsales
Accountsreceivablefromproductsales
4634000 USD
CY2022Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
115000000 USD
CY2021Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
92115000 USD
CY2022Q1 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
1238000 USD
CY2021Q4 halo Allowancefor Distribution Feesand Discounts
AllowanceforDistributionFeesandDiscounts
1140000 USD
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
113762000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
90975000 USD
CY2022Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10267000 USD
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
10672000 USD
CY2022Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6332000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
17451000 USD
CY2022Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
31162000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
25785000 USD
CY2022Q1 us-gaap Inventory Net
InventoryNet
47761000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
53908000 USD
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
57905000 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
47991000 USD
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3091000 USD
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3809000 USD
CY2022Q1 us-gaap Other Assets
OtherAssets
2068000 USD
CY2021Q4 us-gaap Other Assets
OtherAssets
2096000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
63064000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
53896000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
22038000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
13414000 USD
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41026000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
40482000 USD
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19934000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19891000 USD
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12991000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13100000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6943000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6791000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1570000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2003000 USD
CY2022Q1 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8513000 USD
CY2021Q4 halo Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8794000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
700000 USD
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000 USD
CY2021Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
400000 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4194000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9858000 USD
CY2022Q1 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
3674000 USD
CY2021Q4 halo Accruedmanufacturingexpenses
Accruedmanufacturingexpenses
6514000 USD
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9232000 USD
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5793000 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2204000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2820000 USD
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
19304000 USD
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24985000 USD
CY2022Q1 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
171000 USD
CY2021Q4 halo Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
544000 USD
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19133000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24441000 USD
CY2022Q1 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
100000 USD
CY2021Q1 halo Operating Lease Accretion Of Liability
OperatingLeaseAccretionOfLiability
100000 USD
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 USD
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
700000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
700000 USD
CY2019Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
447300000 USD
CY2021Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
369100000 USD
CY2021Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
370200000 USD
CY2021Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
9080000.00 shares
CY2021Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
21000000 USD
CY2021Q1 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
21000000 USD
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
895936000 USD
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
895936000 USD
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
18291000 USD
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
19262000 USD
CY2022Q1 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
877645000 USD
CY2021Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
876674000 USD
CY2022Q1 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
867322000 USD
CY2021Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
878567000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4742000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4923000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4742000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4923000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1300000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
700000 shares
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0137
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0190
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0071
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
550000000 USD
CY2019Q4 us-gaap Stock Repurchase Program Period In Force1
StockRepurchaseProgramPeriodInForce1
P3Y
CY2020 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
6500000 shares
CY2020 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
150000000 USD
CY2020 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
23.05
CY2021 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
4600000 shares
CY2021 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
200000000 USD
CY2021 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
43.02
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
550000000 USD
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
22300000 shares
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
24.72
CY2021Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
750000000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
60108000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
27895000 USD
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137658000 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137952000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
141277000 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148540000 shares
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.44
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.43
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.19
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15400000 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13400000 shares

Files In Submission

Name View Source Status
0001159036-22-000038-index-headers.html Edgar Link pending
0001159036-22-000038-index.html Edgar Link pending
0001159036-22-000038.txt Edgar Link pending
0001159036-22-000038-xbrl.zip Edgar Link pending
ex101agreementforassignmen.htm Edgar Link pending
ex31110qq12022.htm Edgar Link pending
ex31210qq12022.htm Edgar Link pending
ex3210qq12022.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
halo-20220331.htm Edgar Link pending
halo-20220331.xsd Edgar Link pending
halo-20220331_cal.xml Edgar Link unprocessable
halo-20220331_def.xml Edgar Link unprocessable
halo-20220331_g1.jpg Edgar Link pending
halo-20220331_htm.xml Edgar Link completed
halo-20220331_lab.xml Edgar Link unprocessable
halo-20220331_pre.xml Edgar Link unprocessable
image_0.jpg Edgar Link pending
image_10a.jpg Edgar Link pending
image_11a.jpg Edgar Link pending
image_12a.jpg Edgar Link pending
image_13a.jpg Edgar Link pending
image_15a.jpg Edgar Link pending
image_1a.jpg Edgar Link pending
image_3a.jpg Edgar Link pending
image_4a.jpg Edgar Link pending
image_5a.jpg Edgar Link pending
image_6a.jpg Edgar Link pending
image_7.jpg Edgar Link pending
image_8a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending